Nov 11, 2026 · @Yoon Hang Kim MD

Yoon Hang Kim MD Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Dr. Kim is a board-certified physician with over 20 years of clinical experience. A University of Arizona/Andrew Weil fellowship-trained integrative medicine specialist, he holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of eight books and more than 25 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Important: This article is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. The information presented here does not replace individualized medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any treatment.

Introduction

If you spend any time in the LDN community, you've probably heard someone mention seizures. Maybe a parent asked whether LDN could help their child with drug-resistant epilepsy. Maybe a clinician wondered if the anti-inflammatory properties of LDN might quiet an overexcitable brain. It's a fair question — and one that deserves a careful, honest answer.

As someone who has written extensively about LDN and spent years working with clients who use it, I want to be upfront: the evidence here is early. Very early. There is no randomized controlled trial establishing that LDN reduces seizures in humans. What we do have is a single pediatric case series, a handful of preclinical studies in zebrafish and mice, and some plausible biology. That's it.

But "early" doesn't mean "worthless." It means we need to look at what's actually been done, understand its limitations honestly, and figure out where the science needs to go next. That's what this article is about — not hype, not dismissal, just a clear-eyed look at where we stand.

The Human Evidence: One Pediatric Case Series

The only published clinical study on LDN and epilepsy comes from Cairo University. Abokrysha and colleagues published a case series in Neurology India in 2021, and it's worth understanding exactly what they did — and what they didn't do.

Five children with intractable epilepsy — meaning their seizures had not responded adequately to standard antiseizure medications — received LDN at 1 to 5 mg per day on top of their existing treatment. These children ranged in age from approximately 6 to 15 years and were experiencing between 5 and 10 seizures daily at baseline.

The results were encouraging on the surface. The investigators reported marked seizure improvement, and some children achieved seizure freedom during the roughly three-month follow-up. EEG improvements were documented in those who had repeat assessments. A 2026 evidence review noted three children with EEG follow-up, while an Alzheimer's Drug Discovery Foundation assessment reported two children remaining seizure-free for at least three months.

Here's the part that matters for clinical decision-making: this was an uncontrolled case series of five children. No placebo group. No blinding. No randomization. With numbers this small and no comparator, we simply cannot separate the LDN effect from seizure fluctuation, regression to the mean, placebo response, or the influence of whatever else was happening in these children's treatment.

I don't say that to dismiss the findings. I say it because intellectual honesty requires acknowledging that five uncontrolled cases generate a hypothesis — they don't prove a treatment works. If I saw a client's child respond this way, I'd be genuinely interested. But I wouldn't generalize from it, and neither should anyone else.

Preclinical Evidence: Zebrafish, Mouse Models, and What They Mean

The laboratory work is more robust than the clinical evidence, and it tells an interesting story — with significant caveats.

Zebrafish and Mouse Slice Studies (Sturgeon et al., 2021)

Sturgeon and colleagues published a comprehensive set of experiments in Epilepsia Open in 2021. They tested naltrexone across several models:

In a genetic zebrafish model related to Dravet syndrome, naltrexone reduced abnormal seizure-associated locomotion. In chemically induced (PTZ) zebrafish seizures, a similar reduction was observed. In mouse brain slices, naltrexone reduced neocortical epileptiform activity, though there was no statistically significant effect in the hippocampal CA1 region at the concentrations tested. When naltrexone was added to valproate in brain slices, additional suppression was observed. And in living mice given PTZ to induce seizures, naltrexone reduced convulsive seizure number and duration at several doses tested.

These findings are genuinely interesting — but there's a critical translation gap. The mouse doses were 10 to 40 mg/kg administered subcutaneously before the seizure trigger. The more consistent effects came at higher doses, and even then, seizure severity and latency weren't significantly improved across all endpoints. Most importantly, these laboratory exposures bear no established relationship to 1–5 mg/day taken orally by a human being. We cannot assume that "naltrexone works in mice" means "LDN works in people."

Post-Traumatic Seizure Prevention (Rodriguez et al., 2024)

This study, published in Scientific Reports, adds something different to the conversation: the possibility that naltrexone might help prevent epilepsy from developing after a brain injury, rather than merely suppressing seizures after they've started.

Young male mice underwent a traumatic brain injury protocol followed by a subconvulsive PTZ challenge. Naltrexone was given at 40 mg/kg subcutaneously for seven days following injury. The results were striking: late seizures developed in 71% of untreated injured mice but in none of the naltrexone-treated animals. Naltrexone also reduced interictal events and several markers of inflammation and tissue damage.

This is a disease-modification signal, which is conceptually different from — and arguably more exciting than — simply reducing seizure counts. However, the same translation concerns apply: small groups (approximately 7 to 8 mice per EEG group), high-dose parenteral administration, a specialized injury model, and treatment given soon after injury rather than for established epilepsy. None of this tells us whether oral LDN treats or prevents post-traumatic epilepsy in humans.

Proposed Mechanisms: Why LDN Might Work for Seizures

Two overlapping biological explanations have been proposed, and both deserve honest scrutiny.

Opioid Receptor Effects on Neuronal Excitability

Naltrexone blocks opioid receptors, and depending on the receptor subtype, brain region, and experimental conditions, opioid signaling can either promote or suppress seizures. The Sturgeon (2021) study proposes that opioid receptor blockade may reduce excitatory drive in certain neural circuits. But their own discussion acknowledges earlier experiments where naltrexone actually potentiated seizures. The relationship between opioid antagonism and seizure control is more nuanced than "blocking opioid receptors stops seizures."

Modulation of Neuroinflammation

This is the mechanism that gets the most attention in the LDN community, and understandably so — neuroinflammation plays a documented role in some epilepsy syndromes. The pediatric case series invokes TLR4-related microglial modulation as a rationale, and the Rodriguez (2024) mouse study provides actual experimental evidence of changes in mu-opioid receptor signaling, inflammatory pathways, microgliosis, and oxidative stress markers after naltrexone treatment.

But plausible biology is not proof of clinical effect. Neither study demonstrates that LDN doses in humans reduce seizures through TLR4 blockade or any specific anti-inflammatory mechanism. These are reasonable hypotheses — not validated biomarkers for choosing who might respond, and not evidence that what some call "inflammatory epilepsy" will reliably improve with LDN.

What We Still Don't Know

The honest answer to most clinical questions about LDN and seizures is: we don't have the data yet. Here's what remains unanswered:

• Does LDN reduce seizures in adults? No clinical evidence addresses this. The only human data comes from children.
• Does it reliably work in children? Suggested by five uncontrolled cases — not confirmed by any controlled study.
• Which epilepsy syndrome is most likely to respond? Unknown. We have no responder profile.
• Is 4.5 mg nightly the right dose for epilepsy? No epilepsy-specific evidence supports any particular dosing regimen.
• Is LDN synergistic with specific antiseizure medications? An additive effect with valproate was seen in brain slices. That's a laboratory finding, not a clinical combination strategy.
• Can LDN prevent post-traumatic epilepsy? The Rodriguez mouse study is promising, but no human data exists.
• Is long-term use safe in epilepsy populations? The clinical dataset is far too small to answer this.

I list these not to discourage interest but to be transparent about where we actually are. Every one of these questions is answerable — but only through well-designed studies that haven't been conducted yet.

The Clinical Bottom Line

LDN should not replace established antiseizure treatment. It should not delay a comprehensive epilepsy evaluation. And it should not be presented to clients or their families as an evidence-based epilepsy therapy — because the evidence isn't there yet.

That said, I don't think it's unreasonable for an experienced clinician to consider LDN as an experimental adjunct in specific situations — after standard options have been thoroughly addressed, with full transparency about the evidence gap, and with proper monitoring in place.

If a specialist does consider an individual trial, a reasonable framework would include a well-documented pretreatment seizure baseline, stable concurrent antiseizure therapy where feasible, predefined criteria for what counts as a meaningful response, predefined criteria for when to stop, and objective follow-up rather than relying on general impressions of improvement.

This isn't a validated protocol. It's a way to reduce the uncertainty that comes with any off-label trial, and it respects both the client's time and the integrity of the clinical observation.

The most accurate summary for clinicians: LDN has preliminary, uncontrolled clinical evidence in pediatric drug-resistant epilepsy and supportive preclinical evidence for naltrexone's antiseizure and neuroprotective effects. Efficacy, optimal dosing, responder characteristics, and long-term safety in human epilepsy remain unestablished.

I'll be watching this space closely. If a controlled trial emerges, I'll update this article. Until then, honest uncertainty is more useful than premature certainty — in either direction.

Work with Dr. Kim

Dr. Kim offers individualized consultations in integrative and functional medicine through his telemedicine practice, serving clients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. If you're interested in learning more about LDN or exploring whether it may be appropriate for your situation, visit www.directintegrativecare.com to learn about membership options.

For professional consulting, speaking engagements, and media inquiries, visit www.yoonhangkim.com.

References

1. Abokrysha TM, et al. Effect of low-dose naltrexone on Egyptian children with intractable epilepsy: a case series study. Neurology India. 2021;69:1781–1784. doi:10.4103/0028-3886.333523
2. Sturgeon ML, et al. The opioid antagonist naltrexone decreases seizure-like activity in genetic and chemically induced epilepsy models. Epilepsia Open. 2021;6:528–538. doi:10.1002/epi4.12512
3. Rodriguez PJ, et al. Neuroprotective effects of naltrexone in a mouse model of post-traumatic seizures. Scientific Reports. 2024;14:13507. doi:10.1038/s41598-024-63942-8

Yoon Hang Kim MD is the author of MCAS: Epidemic in Plain Sight and LDN Primer*, both available on Amazon, and the founder of the LDN Support Group.*